# Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza

> **NCT05170009** · PHASE2,PHASE3 · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 2 (actual)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** Baloxavir Marboxil
- **DRUG:** Placebo
- **DRUG:** Oseltamivir

## Key facts

- **NCT ID:** NCT05170009
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-22
- **Primary completion:** 2024-01-17
- **Final completion:** 2024-02-07
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Slow enrollment rate
- **Last updated:** 2025-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05170009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05170009, "Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05170009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*